Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Gemcitabine/Irinotecan as Second Line Therapy for Small Cell Lung Cancer

NCT00005972 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT00005972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00005972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Gemcitabine/Irinotecan as Second Line Therapy for Small Cell Lung Cancer
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2000
Completion date
February 29, 2008
Enrollment
73 (actual)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer